Press Room

News / Oct 13, 2023

Hovione shortlisted for the CPhI Pharma Awards 2023!

Hovione shortlisted for the CPhI Pharma Awards 2023!

Hovione_CPhI Pharma Awards 2023

Hovione is once again shortlisted for the prestigious CPhI Pharma Awards 2023!

iSDX – a fully automated, scale representative laboratorial and spray dryer – was nominated in the category of Manufacturing Excellence.



iSDX was designed by Hovione with the aim of developing processes, establishing design spaces, anticipating challenges and producing material representative of commercial scale dryers using a compact lab unit. This is achieved by mimicking the conditions of large dryers in small scale. This dryer was engineered by Hovione using modelling and simulation tools and is routinely used for process development and troubleshooting.



Coupling iSDX with ASD-HIPROS in an integrated offer enables our customers to extensively study and optimize their amorphous solid dispersion formulations while also generating scale representative material for drug product development.



We are thrilled by this nomination which acknowledges our commitment to innovation in pharma and to delivering best-in-class technologies to our customers.

Hovione has the largest number of Spray Drying commercial projects.

Find out how we can support yours.

 

ISDx2_Hovione

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026